For each citation that was shared on social media (LinkedIn, Facebook, or Twitter) with the “@GenScript” tag, the author will be rewarded with a $10 Amazon gift card or 2,000 GS points.

A lymph node-targeted Amphiphile vaccine induces potent cellular and humoral immunity to SARS-CoV-2

Sci Adv. 2021-02; 
Martin P Steinbuck, Lochana M Seenappa, Aniela Jakubowski, Lisa K McNeil, Christopher M Haqq, Peter C DeMuth
Products/Services Used Details Operation
Proteins, Expression, Isolation and Analysis Vaccines consisted of SARS-CoV-2 Spike-2 RBD protein (Genscript; Cat: Z03483) Get A Quote


The profound consequences of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mandate urgent development of effective vaccines. Here, we evaluated an Amphiphile (AMP) vaccine adjuvant, AMP-CpG, composed of diacyl lipid-modified CpG, admixed with the SARS-CoV-2 Spike-2 receptor binding domain protein as a candidate vaccine (ELI-005) in mice. AMP modification efficiently delivers CpG to lymph nodes, where innate and adaptive immune responses are generated. Compared to alum, immunization with AMP-CpG induced >25-fold higher antigen-specific T cells that produced multiple T helper 1 (T1) cytokines and trafficked into lung parenchyma. Antibody responses favored T1 isotypes (IgG2c and IgG3) and potently n... More